Dr. Michael Richard Grunwald, MD

Dr. Grunwald practices at Atrium Health Carolinas Medical Center in Charlotte, North Carolina, part of Advocate Health.

Dr. Grunwald's NPI, 1356495949, was assigned on January 22, 2007. Dr. Grunwald graduated from Johns Hopkins University School of Medicine in 2006. Dr. Grunwald holds North Carolina license 2013-01378.

Dr. Grunwald's primary practice is Atrium Health Carolinas Medical Center, at 1000 Blythe Blvd, Charlotte, NC 28203 in Mecklenburg County. The practice phone is (704) 355-2000.

Dr. Grunwald's primary practice is Atrium Health Carolinas Medical Center in Charlotte, North Carolina, part of Advocate Health. Dr. Grunwald is also affiliated with Atrium Health Wake Forest Baptist Medical Center. The medical group on file is Atrium Health Levine Cancer Institute. Dmand AI also links Dr. Grunwald to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Grunwald practices, 3 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Grunwald's primary specialty in the NPI Registry, under taxonomy code 207RH0000X. The record also lists hematology. Dr. Grunwald is licensed in North Carolina.

CMS data shows 202 Medicare services from Dr. Grunwald across 3 procedure codes in 2024, for 70 Medicare patients. Medicare paid $15,161 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 70 Medicare patients who saw Dr. Grunwald in 2024. The largest group is 75 to 84, with 33 patients. 74% of them have high blood pressure, and 67% have high cholesterol. Their average risk score is 2.50, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Grunwald's median patient age at 71, with 46% women.

In 2024, Dr. Grunwald wrote 751 Medicare Part D claims for 74 patients. 56% of them were for generic drugs. CMS names the drug for 556 of them, across 22 drugs with 11 or more claims each, at $3,568,136 in total drug cost. In 2023, CMS named 521 claims across 21 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Grunwald for performance year 2024, reported as part of a group. Dr. Grunwald accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Grunwald as offering telehealth.

Dmand AI links 70 papers to Dr. Grunwald, published from 2011 to 2025. 2023 was the busiest year, with 11. The most frequent topics are Hematopoietic Stem Cell Transplantation, Transplantation Conditioning and Graft vs Host Disease. Dr. Grunwald has published most often in Blood Adv. Dr. Grunwald's most frequent co-authors are Edward Alan Copelan, MD, Taiga Nishihori, MD and Amer M. Beitinjaneh, MD.

CMS Open Payments shows 526 general payments to Dr. Grunwald from 36 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 79% of the total. Incyte Corporation paid the most, $108,649.

Dr. Grunwald graduated from Johns Hopkins University School of Medicine in 2006.